Journal Article DKFZ-2023-01059

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Effects of vitamin D supplementation on inflammatory response in patients with cancer and precancerous lesions: Systematic review and meta-analysis of randomized trials.

 ;  ;  ;  ;  ;

2023
Elsevier Amsterdam [u.a.]

Clinical nutrition 42(7), 1142-1150 () [10.1016/j.clnu.2023.05.009]
 GO

This record in other databases:  

Please use a persistent id in citations: doi:

Abstract: Inflammation plays a key role in tumor development and progression. Vitamin D has potential tumor suppressing effects through modulation of inflammatory processes. The aim of this systematic review and meta-analysis of randomized controlled trials (RCTs) was to summarize and evaluate the effects of vitamin D3 supplementation (VID3S) on serum inflammatory biomarkers among patients with cancer or pre-cancerous lesions.We searched PubMed, Web of Science and Cochrane databases until November 2022. The effects of VID3S were estimated from pooled standardized mean differences (SMDs) with their 95% confidence intervals (CIs) for inflammatory biomarker follow-up levels between intervention and control groups.Meta-analysis of eight RCTs (total of 592 patients with cancer or pre-cancerous conditions) showed that VID3S significantly lowered levels of serum tumor necrosis factor (TNF)-α (SMD [95%CI]: -1.65 [-3.07; -0.24]). VID3S also resulted in statistically non-significantly lower serum levels of interleukin (IL)-6 (SMD [95%CI]: -0.83, [-1.78; 0.13]) and C-reactive protein (CRP) (SMD [95%CI]: -0.09, [-0.35; 0.16]), whereas IL-10 levels were unaltered (SMD [95%CI]: -0.00, [-0.50; 0.49]).Our study shows evidence of a significant reduction of TNF-α levels by VID3S for patients with cancer or precancerous lesions. Patients with cancer or precancerous lesions may benefit from personalized VID3S in suppressing tumour-promoting inflammatory response.CRD42022295694.

Keyword(s): Biomarker ; Cancer ; Inflammation ; Precancer ; Vitamin D3 supplement

Classification:

Note: 2023 Jul;42(7):1142-1150 / #EA:C120#LA:C120#LA:C070#

Contributing Institute(s):
  1. Präventive Onkologie (C120)
  2. C070 Klinische Epidemiologie und Alternf. (C070)
  3. DKTK HD zentral (HD01)
Research Program(s):
  1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2023
Database coverage:
Medline ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF >= 5 ; JCR ; NationallizenzNationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Public records
Publications database

 Record created 2023-05-30, last modified 2024-02-29



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)